Deamidated Gliadin

Monoclonal antibody to deamidated and non-deamidated Gliadin



Order
Quantity
Price
Status
100 µg 495 € available


Documents
Art. No. A161
Background info Tissue transglutaminase (TG2) catalyses gliadin deamidation in the intestinal mucosa of celiac disease patients, resulting in deamidated gliadin peptides which are recognized by HLA receptors (DQ2/DQ8) of immune cells. Antibodies to deamidated gliadin have been proven to be specific for celiac disease – in contrast to gliadin antibodies. Detection of deamidated gliadin antibodies now is used in celiac disease diagnostics.
Host Mouse
Clone ZDG-02
Isotype IgG2a/k
Immunogen Deamidated gliadin-related peptide Lys57-Glu65-[α-gliadin (58-73)] (KLQPFPQPELPYPQPQ).
Specificity Recognizes Gliadin. Reacts equally strong with both the deamidated peptide (KLQPFPQPELPYPQPQ) and the non-deamidated peptide (KLQPFPQPQLPYPQP) when coated directly in an immunoplate.
Appearance liquid, 100 μL with ~1 mg/mL
Description The antibody is supplied as a liquid in PBS, pH 7.4
Application Suitable for use in ELISA and Western Blot. Other applications not tested.
Working dilutions Optimal dilutions should be determined by the end user.
The following are guidelines only:
ELISA: 1 / 64,000
Western-Blot: 1 / 1,000
Storage Stable for short term at + 4 °C
For extended periods: store aliquots at – 20 °C
Reference(s) Skovbjerg et al., Biochim. Biophys. Acta. 2004, 1690, 220-30
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy